Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7569610 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
US7585897 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
US7572935 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
US7662407 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
US7645802 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(3 years from now) | |
US7671094 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(3 years from now) | |
US7649019 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
US7241805 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) |
Market Authorisation Date: 23 April, 2008
Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours
Dosage: TABLET, EXTENDED RELEASE;ORAL
24
United States
8
European Union
4
Canada
3
Russia
3
China
3
Japan
3
Korea, Republic of
3
Australia
3
South Africa
2
Nicaragua
2
New Zealand
2
Mexico
2
Costa Rica
2
Ecuador
2
Colombia
1
Hong Kong
1
Ireland
1
Singapore
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic